Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study looks inside the womb to see how opioid medications impact unborn babies

NCT ID NCT03911466

Knowledge-focused Sponsor: T. John Winhusen, PhD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at pregnant women being treated for opioid use disorder with two different forms of buprenorphine: a monthly shot and a daily tablet. Researchers measured drug levels in the mother's blood and checked the baby's heart rate to see how each treatment affected both mother and child. The goal was to understand which approach might lead to better outcomes for newborns, including reducing withdrawal symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

97 people

The number who actually took part.

Started

Jul 2020

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants in this study were recruited from the main CTN-0080 MOMs (NCT03918850) study sample.

Ages

18 to 41 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participating in the MOMs trial (Unique protocol ID: 2019-0429-1) Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug abuse are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

drug dependence neonatal abstinence syndrome opiate dependence pregnancy disorder substance abuse substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Drug abuse Drug abuse in pregnancy Drug addiction Neonatal abstinence syndrome Neonatal opioid withdrawal syndrome Opioid-related disorders Pregnancy related Substance abuse

Contacts and locations

Locations

  • Addiction Recovery Services (ARS), Swedish Medical Center

    Seattle, Washington, 98107, United States

  • Boston Medical Center

    Boston, Massachusetts, 02118, United States

  • CODA, Inc.

    Portland, Oregon, 97214, United States

  • Gateway Community Services

    Jacksonville, Florida, 32204, United States

  • Marshall Health MARC Program

    Huntington, West Virginia, 25701, United States

  • Massachusetts General Hospital HOPE Clinic

    Boston, Massachusetts, 02114, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • Pregnancy Recovery Center at Magee-Womens Hospital of UPMC

    Pittsburgh, Pennsylvania, 15213, United States

  • University of Cincinnati Health Perinatal Addictions Program

    Cincinnati, Ohio, 45229, United States

  • University of New Mexico Milagro Clinic

    Albuquerque, New Mexico, 87106, United States

  • University of Utah SUPeRAD Clinic

    Salt Lake City, Utah, 84108, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.